No immediate trading action warranted. Monitor the Q1 FY2027 earnings call for any guidance updates or commentary on underlying segment performance under the new structure.
Price Chart
Executive Summary
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood Center segments into a single 'Apheresis' segment and renaming the Hospital segment to 'MedSurg', effective Q1 FY2027. The company posted recast historical revenue and a recast of previously issued FY2027 guidance to align with the new structure, but explicitly stated it is not reaffirming or updating that guidance. This is a routine administrative reorganization with no new financial data or change in outlook.
Key Facts
- Haemonetics transitions from three reportable segments to two: Apheresis (combined Plasma + Blood Center) and MedSurg (renamed from Hospital).
- New segment structure effective Q1 FY2027, which began March 29, 2026.
- Company posted recast historical revenue for FY2024-2026 and recast FY2027 guidance on its IR website.
- Company explicitly states the recast is not a reaffirmation or update of previously issued FY2027 guidance.
- No financial figures, guidance changes, or material business developments were disclosed.
Financial Impact
No financial impact — segment reclassification only, no new numbers or guidance changes.
Risk Factors
- Segment reclassification may cause temporary confusion in financial models until analysts adjust.
- No reaffirmation of guidance could be interpreted negatively if the market was expecting an update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000313143-26-000057 |
| Exhibit: ex991-pressrelease652026.htm | 0000313143-26-000057 |
| Document: 0000313143-26-000057-index-headers.html | 0000313143-26-000057 |
| Document: 0000313143-26-000057-index.html | 0000313143-26-000057 |
| Document: 0000313143-26-000057.txt | 0000313143-26-000057 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 6w ago | 8-K | $104.65 $105.68 | ▲ +0.98% | ▲ +1.97% | $104.68 (+0.03%) |
Jun 9, 2026 16w ago | DEFA14A | $78.80 $75.00 | ▼ −4.82% | ▼ −8.45% | $104.68 (+32.84%) |
Jun 5, 2026 17w ago | 8-K | $71.28 $75.02 | ▲ +5.25% | ▲ +3.39% | $104.68 (+46.86%) |
May 7, 2026 21w ago | 8-K | $54.37 $65.88 | ▲ +21.17% | ▲ +18.03% | $104.68 (+92.53%) |
May 1, 2026 22w ago | 8-K | $55.32 $67.22 | ▲ +21.51% | ▲ +15.87% | $104.68 (+89.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access